The FDA has announced a nationwide shortage of The commercial version of Hydroxyprogesterone Caproate Injection (aka, 17P). The trade name is Makena.

17P injection has been demonstrated to reduce the risk of preterm birth in women who have a history of delivering less than 37 weeks.

Special compounding pharmacies have been safely making this sterile preparation since long before the Makena company began commercial production in 2012. These pharmacies have continued to successfully make 17P injections. The basic ingredients are readily available.

The Compounder Pharmacy is experienced and prepared to meet the need for 17P injections.

Each order is prepared as a prescription for a single patient. The order is routinely paid for by the patient and delivered to the prescribing doctor for administration in the office. Some patients self-administer.

Interested persons can contact the pharmacists at The Compounder Pharmacy for additional information and to answer questions. Use the “Ask Larry” link at the bottom of this page.